Johnson & Johnson announced new results from the Phase 2 RedirecTT-1 study evaluating the investigational combination of TALVEY, the first U.S. Food and Drug Administration-approved GPRC5D-directed bispecific antibody, and TECVAYLI, the first FDA-approved BCMA-directed bispecific antibody. The results show a high overall response rate with durability in patients with triple-class exposed relapsed/refractory multiple myeloma who have true extramedullary disease, EMD. EMD is defined as soft tissue/organ-associated plasmacytomas with no contact to bony structures as per International Myeloma Working Group criteria. RedirecTT-1 is the largest study dedicated to patients with EMD to date. These data were featured in a late-breaking oral presentation at the 2025 European Hematology Association Congress.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Johnson & Johnson announces clinical data from Phase 1b study of JNJ-4496
- Strategic Positioning and Growth Potential Drive Buy Rating for Johnson & Johnson
- Healthcare Sector Taps AI Boom via Intuitive Surgical Stock (ISRG)
- Senators to propose ban on drug ads to consumers, WSJ reports
- JPMorgan biotech/pharma analysts hold analyst/industry conference call
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue